Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
ESMO Open ; 7(2): 100408, 2022 04.
Article in English | MEDLINE | ID: mdl-35279527

ABSTRACT

BACKGROUND: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically improved OS versus EP, but did not reach statistical significance. Here we report updated OS in censored patients after median follow-up of >3 years. PATIENTS AND METHODS: 805 patients with treatment-naïve ES-SCLC were randomized 1 : 1 : 1 to durvalumab plus EP, durvalumab plus tremelimumab plus EP, or EP. The two primary endpoints were OS for durvalumab plus EP versus EP and for durvalumab plus tremelimumab plus EP versus EP. RESULTS: As of 22 March 2021 (median follow-up 39.4 months, 86% maturity), durvalumab plus EP continued to demonstrate improved OS versus EP: hazard ratio (HR) 0.71 [95% confidence interval (CI) 0.60-0.86; nominal P = 0.0003]; median OS was 12.9 versus 10.5 months, and 36-month OS rate was 17.6% versus 5.8%. Durvalumab plus tremelimumab plus EP continued to numerically improve OS versus EP: HR 0.81 (95% CI: 0.67-0.97; nominal P = 0.0200); median OS was 10.4 months, and 36-month OS rate was 15.3%. Twenty-seven and nineteen patients in the durvalumab plus EP and durvalumab plus tremelimumab plus EP arms, respectively, remained on durvalumab treatment at data cut-off. CONCLUSIONS: Three times more patients were estimated to be alive at 3 years when treated with durvalumab plus EP versus EP, with the majority still receiving durvalumab at data cut-off, further establishing durvalumab plus EP as first-line standard of care for ES-SCLC.


Subject(s)
Lung Neoplasms , Small Cell Lung Carcinoma , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Etoposide/therapeutic use , Humans , Lung Neoplasms/drug therapy , Platinum/therapeutic use , Small Cell Lung Carcinoma/drug therapy
2.
Morfologiia ; 118(5): 36-40, 2000.
Article in Russian | MEDLINE | ID: mdl-11452425

ABSTRACT

Anatomical variants of three-dimensional shape of rabbit thymus were studied by method of plastic reconstruction. 11 age groups were used (94 animals in total). Individual and age variants of three-dimensional shape of thymus and its lobes, areas and character of their conjugation, spatial orientation and participant of different regions of the lobes in formation of the general level, lateral margin and cardiac notch were described. Dolychomorphic, mesomorphic and brachiomorphic variants of thymus shape were distinguished in rabbit. Significant participant of right lobe in formation of cardiac inlet was demonstrated.


Subject(s)
Thymus Gland/anatomy & histology , Animals , Animals, Newborn , Gestational Age , Morphogenesis , Rabbits , Thymus Gland/embryology , Thymus Gland/growth & development
SELECTION OF CITATIONS
SEARCH DETAIL
...